Catechol-O-methyltransferase (COMT) is one of several enzymes that degrade catecholamines such as dopamine, epinephrine, and norepinephrine. And the regulation of catecholamines is impaired in a number of medical conditions. This study ahead of print suggests that COMT is higher in patients with psoriasis, but can be reduced with Narrowband UVB treatment.

Background:
Narrowband ultraviolet B (nbUVB) phototherapy is widely used in psoriasis treatment. UVB irradiation decreases catechol-O-methyltransferase (COMT) activity in human keratinocytes and melanoma cells. COMT activity is higher in psoriatic lesions than in normal skin but the effect of nbUVB on COMT activity in psoriasis patients is unknown.

Objectives:
To evaluate COMT activity in patients with psoriasis and determine whether nbUVB modifies this activity.

Methods:
An open observational study was conducted with 20 psoriasis patients and 15 healthy volunteers. Patients were treated with nbUVB thrice weekly during six weeks and evaluated at baseline, three and six weeks after phototherapy and four weeks after stopping. In each evaluation body mass index (BMI), Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were calculated and blood samples for erythrocytes soluble (S-) COMT activity assessment were taken.

Results:
Before phototherapy (baseline), using a single concentration of substrate adreneline (1,000 μM), S-COMT activity levels (pmol/mg protein/h) were significantly higher in psoriasis patients than in controls. After nbUVB treatment, S-COMT activity significantly decreased. This decrease correlated positively with baseline activity. Four weeks after stopping phototherapy, S-COMT activity returned to baseline levels. After phototherapy, PASI score improved significantly but no correlation to baseline S-COMT values or decrease in S-COMT activity was found.

Conclusions:
This study shows that baseline S-COMT activity is higher in psoriasis patients than in controls and that this activity is significantly decreased by nbUVB treatment for psoriasis. This decrease is more evident in patients with higher baseline S-COMT activity.

Source: NO LINKS ALLOWED

mTOR (mammalian target of rapamycin) also known as mechanistic target of rapamycin or FK506 binding protein 12-rapamycin associated protein 1 (FRAP1) is a protein which in humans is encoded by the FRAP1 gene. mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family.

This study published in the British Journal of Dermatology suggests that mTOR inhibition might be a mode of action suitable to be explored for a new psoriasis treatment.

Background:
mTOR (mammalian target of rapamycin) signalling integrates signals leading to cellular growth, proliferation and differentiation. Disturbance of this tightly regulated interplay leads to malignancies, as reflected by altered mTOR signalling in epidermal tumours. As psoriatic keratinocytes also show features of perturbed cell growth and differentiation, the question arises whether mTOR signalling also plays a role in the pathogenesis of psoriasis.

Objectives:
Investigation of the activation status of mTOR signalling components in psoriasis

Methods:
Biopsies from lesional and non-lesional skin of psoriasis patients (n=10) as well as samples from healthy donors (n=3) were analysed by immunohistochemistry and Western blot, utilizing antibodies detecting phosphorylated mTOR (P-mTOR), P-S6K and P-S6 ribosomal protein.

Results:
We found mTOR and its downstream signalling molecule, the ribosomal protein S6 to be activated in lesional psoriatic skin. While mTOR is activated throughout the whole epidermis, with particularly strong activation in the basal layer, S6 is rather active in suprabasal layers of differentiating keratinocytes.

Conclusions:
Altogether these results suggest a role for mTOR signalling in the epidermal changes leading to the psoriatic phenotype. mTOR inhibition might be a mode of action suitable to be explored for innovative anti-psoriatic drugs.

Source: NO LINKS ALLOWED

This study published in the British Journal of Dermatology looks at efficacy, safety and tolerability of different topical treatments used in plaque psoriasis. It suggests that Corticosteroids are highly effective, and Coal tar and retinoids are of limited benefit. (Topical Treatments are applied directly to the skin)

Background:
The majority of people with psoriasis have localised disease, where topical therapy forms the cornerstone of treatment.

Objective:
To summarise evidence on relative efficacy, safety and tolerability of different topical treatments used in plaque psoriasis

Methods:
Systematic review and meta-analyses of randomised trial data of UK-licensed topical therapies. The primary outcome was clear or nearly clear status stratified for (i) trunk and limbs and (ii) scalp. Network meta-analyses allowed ranking of treatment efficacy.

Results:
48 studies were available for trunk and limb psoriasis and 17 for scalp psoriasis (n=22,028); the majority included people with at least moderate psoriasis severity. Strategies containing potent corticosteroids (alone or in combination with a vitamin D analogue) or very potent corticosteroids, dominated the treatment hierarchy at both sites (trunk and limbs, scalp); coal tar and retinoids were no better than placebo. No significant differences in achievement of clear/nearly clear status were observed between twice and once daily application of the same intervention or between any of the following: combined vitamin D analogue and potent corticosteroid (applied separately or in a single product), very potent corticosteroids, or potent corticosteroids (applied twice daily). Investigator and patient assessment of response differed significantly for some interventions (response rate to very potent corticosteroids 78% and 39% respectively). No significant differences were noted for tolerability or steroid atrophy, but data were limited.

Conclusions:
Corticosteroids are highly effective and safe in psoriasis when used continuously for up to 8 weeks and intermittently for up to 52 weeks. Coal tar and retinoids are of limited benefit. There is a lack of long-term efficacy and safety data available on topical interventions used for psoriasis.

Source: onlinelibrary.wiley.com

Oral Thrush (oral candidiasis) is a common yeast infection of the Candida species on the mucous membranes of the mouth, this study suggests that the presence of oral thrush is higher in patients with psoriasis



Background:
Infections are known to trigger and exacerbate psoriasis. Although oral candidiasis is often clinically diagnosed, it is not always confirmed by laboratory tests such as oral cytopathology.

Objectives:
The aims of this study were to determine the prevalence of oral candidiasis in patients with psoriasis through clinical and cytopathological diagnosis and to investigate the association between oral candidiasis and psoriasis with regards to the severity of the clinical presentation and the type of treatment for psoriasis.

Methods:
A total of 140 patients with psoriasis and 140 healthy control subjects received an oral examination. Scrapings of the tongue were also obtained for a cytopathological examination.

Results:
The oral examination and the results of the cytopathological smear revealed 37 (26%) cases of candidiasis in the patients with psoriasis and no cases of candidiasis in the healthy control subjects. There was no correlation between the type of psoriasis treatment and the presence of oral candidiasis (P = .616). There was a statistically significant association (P = .033) between the clinical severity of psoriasis and the presence of Candida.

Limitations:
This study was limited by the small number of subjects and the lack of follow-up to determine the development of psoriasis after treatment for oral candidiasis.

Conclusions:
The presence of oral candidiasis is higher in patients with psoriasis and it is associated with disease severity. This increased presence of oral candidiasis was apparent despite any type of treatment for the psoriasis. Cytopathology to rule out oral candidiasis should be used in the routine medical workup of patients with psoriasis.

Source: NO LINKS ALLOWED

Other relevant posts.
Gum disease linked to psoriasis
Psoriasis and oral health
Your Tongue can say a lot

Hello,
I am new to P as I have had it only for about 6 monts. Now my joints in my fingers and toes are clearly affected. What will happen when I go to the doctor. Do I have to go to a specialist, do I have to have many x-rays or other tests et.c.

The Adacolumn is a Japanese adsorptive type extracorporeal leukocyte apheresis device that selectively adsorbs granulocytes, monocytes/macrophages by Fcγ and complement receptor bindings.

Approximately 65% of granulocytes and 55% of monocytes from the blood that passes
through the column are adsorbed. However the total number of blood cells remains constant as the removed cells are rapidly replaced by mobilisation of inactive, CD-10 negative leukocytes.



Background:
Generalized pustular psoriasis (GPP) is a chronic autoimmune disease characterized by fever, erythema, and neutrophilic pustules over large areas of the skin. GPP does not respond well to pharmacologic intervention.

Objective:
We sought to assess efficacy of selectively depleting the myeloid lineage leukocytes in patients with GPP.

Methods:
Fifteen patients with persistent moderate to severe GPP despite conventional therapy were included. Eligible patients had more than 10% of their skin area covered by pustules. Treatment with oral etretinate, cyclosporine, methotrexate, prednisolone, and topical prednisolone/vitamin D3 was continued if had been initiated well in advance of study entry.
Five sessions of adsorptive granulocyte and monocyte apheresis (GMA) with the Adacolumn (JIMRO Co Ltd, Takasaki, Japan) were administered (1 session/wk over 5 weeks) to selectively deplete Fcγ receptor and complement receptor bearing leukocytes. Efficacy was assessed by measuring the skin areas covered by pustules at baseline and 2 weeks after the last GMA session.

Results:
One patient did not complete the first GMA session. Based on the GPP severity scores relative to entry, the overall scores improved (n = 14, P = .0027), and the area of erythroderma (P = .0042), pustules (P = .0031), and edema (P = .0014) decreased. Likewise, Dermatology Life Quality Index improved (P = .0016), reflecting better daily function and quality of life. Twelve patients were judged as responders (85.7%), and 10 patients maintained the clinical response for 10 weeks after the last GMA session without any change in medication.

Limitations:
This study was unblinded and without a placebo arm.

Conclusion:
GMA in this clinical setting was safe and effective, suggested a major role for granulocytes/monocytes in the immunopathogenesis of GPP.

Source: jaad.org

Tofacitinib is a drug being investigated by Pfizer for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection.

In November 2012 the U.S. Food and Drug Administration (FDA) approved it for treatment of rheumatoid arthritis. Tofacitinib is an inhibitor of the enzyme Janus kinase 3. More on that here: RE: I need more Psoriasis

Background:
Tofacitinib (CP-690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory diseases including psoriasis.

Objectives:
This Phase 2a study aimed to assess the efficacy, systemic safety, local tolerability and systemic pharmacokinetics of topical tofacitinib in mild-to-moderate plaque psoriasis.

Methods:
Two tofacitinib ointment formulations were evaluated in this multicentre, double-blind, vehicle–controlled trial (NCT01246583). Seventy-one patients were randomised 2:1:2:1 to 2% tofacitinib Ointment 1, Vehicle 1, 2% tofacitinib Ointment 2 and Vehicle 2, each administered twice daily for 4 weeks to a single fixed 300 cm2 treatment area containing a target plaque +/- one or more non-target plaques and normal skin.

Results:
The primary endpoint of percent change from baseline in Target Plaque Severity Score at Week 4 demonstrated statistically significant improvement for Ointment 1 (least squares mean [LSM] –54.4%) vs Vehicle 1 (LSM –41.5%), but not Ointment 2 (LSM –24.2%) vs Vehicle 2 (LSM –17.2%). Secondary endpoints (Target Plaque Area and Itch Severity Item) improved similarly for tofacitinib ointment vs corresponding vehicle. Adverse event (AE) occurrence was similar across treatment groups. All AEs were mild or moderate and none were serious or led to subject discontinuation. One application site AE (erythema) was reported. Tofacitinib mean systemic exposure was minimal and was greater for Ointment 1 than for Ointment 2.

Conclusions:
Tofacitinib Ointment 1 was well tolerated and efficacious compared with vehicle for the treatment of plaque psoriasis. Further study of topical tofacitinib for psoriasis treatment is warranted.

Source: onlinelibrary.wiley.com

Hello!! I have been "living" with psoriasis since May 26, 1995. I remember it because i had my 16th bday on the 4th..then i had my first baby on the 19th and i remember i had a skirt i was so excited about wearing since i had lost enough baby weight to fit into it...i was also going to look at a apartment with a friend of mine i had known since public school (kindergarten) ...i can remember it like it was this morning...

i got the skirt out and laid it on my bed..went into the bathroom to take a shower and thats when it happened...i noticed there was a long line of "spots" down my shin, i freaked out...went directly to my papa and asked him what it was, he thought it was hayfever and gave me a bunch of benedryl and sent me on my way. A few days later it covered my legs completely, most of my stomach and chest, also my arms were covered, the palms of my hands and face were just red and itchy.
psoriasis had taken over my body.

bless papa's heart he tried so hard to rid me of this horrible skin condition, taking me to any doctor he could find. My friends treated me like i had something contagious and left me to myself, the boyfriend was no help and my parents had no clue...

no one in my family has psoriasis (my father took off when i was born so i have no idea about his family...which is probably where it is from but like i say i have never had contact with them)

I have tried EVERYTHING available to me from creams, tar, UV lights, tanning beds, diet, methotrexate oral and injection and now i am at the max dose for the methotrexate injection but it makes me so unbelievably nauseas that i cannot handle it any longer, now my 10yr old has it on her scalp and face, she is mortified and rightfully so, the biggest problem i am having is she is autistic and feels pain differently then we do and she scratches the spots until she bleeds. i have not sent her to school as kids are extremely cruel and i cannot stand to subject her to that.

i need some help!
i have a dermatologist appointment for her on the 22snd of feb and hope the doc can help her...i refuse to treat mine until i can relieve her of hers.

i hope i have done my introduction properly and look forward to many conversations with the great members of this club!!

thank you for inviting me!

cheers! tammie

Galapagos a clinical stage biotech company based in Belgium today announced that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.

GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ osteoarthritis alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK €34M in additional milestones plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.

“Inhibition of JAK1 is considered a promising new therapeutic route to treat inflammatory diseases. Galapagos is leading the field with two JAK1 inhibition molecules being tested in patients,” said Onno van de Stolpe, CEO of Galapagos. “With two of our JAK1 molecules in Phase 2, we hope that this will deliver a new class of medicines to patients with inflammatory diseases.”

GSK plans to initiate a 12 week, multi-center, dose-ranging, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients. Furthermore, GSK will also initiate a 12 week multi-center, dose-ranging, placebo-controlled Phase 2 study investigating the efficacy and safety of GSK2586184 in chronic plaque psoriasis.

Source: glpg.com

This study published in the British Journal of Dermatology set out to find the cost effectiveness of topical therapies for the treatment of localised plaque psoriasis.

Background:
Topical therapies are a mainstay of psoriasis treatment, but they vary substantially in terms of costs.

Objectives:
To determine the cost-effectiveness and optimal treatment sequence for psoriasis of the trunk, limbs and scalp.

Methods:
Probabilities of response from a network meta-analysis were used to determine the short-term efficacy of topical therapies. Longer-term outcomes, including relapse, were informed by published evidence and clinical opinion. Benefits of treatment were measured as quality-adjusted life years (QALYs). Direct costs included topical agents, primary and secondary care visits and second-line therapies for treatment failures.

Results:
For trunk and limbs, initial treatment with two-compound formulation (TCF) product containing vitamin D and potent corticosteroid provided the most QALYs, followed by separate morning and evening application of vitamin D and potent corticosteroid (TCA (am/pm)), and then twice daily potent corticosteroids. Twice daily potent corticosteroid was the most cost-effective first-line strategy (ICER £20,000 per QALY), followed by TCA (am/pm) (£22,658 per QALY) and TCF product (£179,439 per QALY). For scalp psoriasis, initial treatment with very potent corticosteroids generated the most QALYs, followed by TCF product and then potent corticosteroids. Very potent corticosteroids were most cost effective, but if too aggressive, then potent corticosteroids were optimal followed by TCF product (£219,846 per QALY). Cost effectiveness of second and third-line topical agents varied with assumptions made.

Conclusions:
Potent corticosteroids, used alone or in combination with vitamin D are most cost-effective for patients with psoriasis of the trunk and limbs. Potent or very potent corticosteroids are most cost-effective for patients with scalp psoriasis.

Source: NO LINKS ALLOWED

Topical therapies are applied directly to the skin.

This thread explains the difference between Dovobet And Dovonex https://psoriasisclub.org/showthread.php?tid=75

Hi my  name is Ladonna but everyone call me Ms Donna. I have been married for 13 years in May my anniversary I have 4 children two men and set of teen girls age 12 . What keeps me grounded with my psoriasis is music.

I'm new here and I'm just looking for answers.

This article published in the British Journal of Dermatology set out to assess the efficacy and safety of different doses of Novartis AIN457 (secukinumab) for the treatment of moderate-to-severe plaque psoriasis.

Background: 
Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long-term safety. Interleukin (IL)-17A is believed to be an important effector cytokine in the pathogenesis of psoriasis and is produced by Th17 cells, a class of helper T cells that act outside the established Th1/Th2 paradigm for regulation of innate and adaptive immunity.

Objectives: 
To assess the efficacy and safety of different doses of secukinumab, a fully human anti-IL-17A IgG1κ monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.

Methods: 
Patients (n = 125) were randomized 1 : 1 : 1 : 1 : 1 to receive subcutaneous doses of placebo (n = 22) or secukinumab [1 × 25 mg (n = 29), 3 × 25 mg (n = 26), 3 × 75 mg (n = 21) or 3 × 150 mg (n = 27)] at weeks 0, 4 and 8. After the 12-week treatment period, patients entered a follow-up period of 24 weeks. The primary efficacy outcome was at least 75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 75); secondary outcomes included the Investigator’s Global Assessment (IGA) and PASI 90 and 50 response rates.

Results: 
After 12 weeks of treatment, secukinumab 3 × 150 mg and 3 × 75 mg resulted in significantly higher PASI 75 response rates vs. placebo (82% and 57% vs. 9%; P < 0·001 and P = 0·002, respectively). Higher PASI 75 response rates compared with placebo were maintained throughout the follow-up period with these dosages [week 36, 26% (n = 7) and 19% (n = 4) vs. 4% (n = 1), respectively], with a gradual decline of PASI 75 response over time after the dosing period. IGA response rates were significantly higher in the 3 × 150 mg group vs. placebo at week 12 (48% vs. 9%; P = 0·005) and were consistently higher for the 3 × 150 mg and 3 × 75 mg groups vs. placebo at all time points from week 4 onward. The PASI 90 response rate was significantly higher in the 3 × 150 mg group vs. placebo (52% vs. 5%) at week 12 and remained higher during the follow-up period. Secukinumab was well tolerated. Two cases of neutropenia (≤ grade 2) were reported in the 3 × 150 mg cohort.

Conclusions: 
Treatment with subcutaneous secukinumab 3 × 75 mg and 3 × 150 mg met the primary outcome of PASI 75 response achievement after 12 weeks, demonstrating efficacy in moderate-to-severe psoriasis.

Source: NO LINKS ALLOWED

Novartis AIN457 (secukinumab) Phase II Report: https://psoriasisclub.org/showthread.php?tid=237

Do you think a daily text message could help you with your psoriasis? A study published in the British Journal of Dermatology suggests that a daily text message providing reminders and educational tools could help!

Background: 
Psoriasis is a chronic disease which requires long-term therapy. Therefore, adherence to therapy and patient motivation are key points in controlling the disease. Mobile-phone-based interventions, and in particular text messages ™, have already been used effectively to motivate patients and improve treatment adherence in many different chronic diseases such as diabetes, cardiovascular disease and asthma.

Objectives: 
To evaluate the use of TM in improving treatment adherence and several patient outcomes such as quality of life, disease severity, patient-perceived disease severity and the patient–physician relationship.

Patients and methods: 
Daily TM, providing reminders and educational tools, were sent for 12 weeks to a group of 20 patients with psoriasis. At the beginning and end of the study the following assessments were performed: Psoriasis Area Severity Index (PASI), Self-Administered Psoriasis Area Severity Index (SAPASI), body surface area (BSA), Physician Global Assessment (PGA), Dermatology Life Quality Index (DLQI), evaluation of patient–physician relationship and adherence to therapy. A matched control group of 20 patients with psoriasis was used for comparison of the same outcomes.

Results: 
Both patient groups had similar scores for PASI, SAPASI, BSA, PGA and DLQI at baseline. However, after 12 weeks the intervention group reported a significantly better improvement of disease severity as well as quality of life, showing lower values of PASI, SAPASI, BSA, PGA and DLQI with respect to the control group (P < 0·05). Moreover, adherence to therapy improved in a statistically significant way (P < 0·001) whereas it remained stable in the control group. Similarly, TM interventions led to an optimization of patient–physician communication.

Conclusions: 
TM interventions seem to be a very promising tool for the long-term management of patients with psoriasis, leading to an increased compliance to therapy, positive changes in self-care behaviours and better patient–physician relationship allowing improved clinical outcomes and better control of the disease.

Source: onlinelibrary.wiley.com

This report from The British Journal of Dermatology shows nine out of ten sunbeds surveyed in England emitted levels of UV radiation that exceed the maximum levels contained within the European standard.

Background: 
Exposure to ultraviolet (UV) radiation from sunlight is recognized as the principal cause of skin cancer. Moreover, sunbeds have been classified as carcinogenic by the International Agency for Research on Cancer. Despite this, there is a shortage of objective data on UV exposure levels in sunbeds in England.

Objectives: 
We set out to measure UV emission levels in sunbeds at sites around England, and to compare these levels with both current standards and natural sunlight.

Methods: 
Between October 2010 and February 2011, UV spectra were measured on site from a total of 402 artificial tanning units in England. Measurement instrumentation was calibrated, traceable to the National Physical Laboratory. Compliance with the relevant British and European standard was determined, and a skin-cancer weighting factor was used to compare the carcinogenic potential of sunbeds with that of sunlight.

Results: 
For compliance with the European standard, erythemal-effective irradiance should not exceed 0·3 W m−2. The values that we measured ranged between 0·10 and 1·32 W m−2 with a mean of 0·56 ± 0·21 W m−2. Only 10% of sunbeds surveyed were within the recommended limit. Application of the skin-cancer weighting factor produced values that varied from 0·17 to 2·52 W m−2 with a mean of 0·99 ± 0·41 W m−2. The comparable value for Mediterranean noonday sun was 0·43 W m−2.

Conclusions: 
Nine out of 10 sunbeds surveyed throughout England emitted levels of UV radiation that exceed the maximum levels contained within the European standard. Moreover, the skin cancer risk for comparable times of exposure was up to six times higher than that for Mediterranean sunlight. This situation is unacceptable and stricter control measures must be put in place.

Source: onlinelibrary.wiley.com

I've been playing with a new feature "Random Thread"

It's only available to members that are logged in, and you can find it on the menu at Random Thread and in the footer at Random.

Just click it and you should be taken to a random thread from the forum that you may have missed.

Any problems or questions please let me know.

Biocon India's largest biotechnology company by revenue announced today that it has received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis.

Quote:

---

Itolizumab, is a first in class therapy with a unique Mechanism of Action (MOA) and an excellent safety profile as indicated during the 52 week Phase III multi-centric clinical study conducted in India. It is the second Novel Biologic developed by Biocon at Asia’s largest Biotech hub in Bangalore.

This approval paves the way for the launch of Biocon’s Alzumab in India, later during 2013. Alzumab is a differentiated biologic drug with a superior safety profile compared to other approved biologic therapies given its very low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab will be marketed by Biocon’s Immunotherapy Division. Alzumab, will be manufactured and formulated as an infusion drug at Biocon’s Biopharma manufacturing facility at Biocon Park, Bangalore.

Commenting on this development Ms. Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon said, “We are very excited to receive this marketing authorization for Itolizumab from DCGI which will enable Biocon to introduce this novel, first in class biologic for the treatment of psoriasis patients in India. This is our Second novel biologic that we have developed in India, BioMab EGFR, an anti-cancer monoclonal antibody, being the first. This approval paves the way for us to extend clinical development for other indications like Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Vitiligo. We also intend to file a US IND shortly to enable us to embark on a global clinical development plan. This is a defining moment for Biocon as it reaches a significant milestone in its mission of delivering affordable innovation to patients worldwide.”

I have a mild case of scalp psoriasis that is one persistant mofo' and it's recently developed in my ears,i had no idea that could even happen.. and every now and again minor lesions appear on my legs or elbows or even my face and every timethese minor lesions appear itry to apply just som regular cream asmuch as i can because the ointments tend to bleach skin, something i learned the hard way. Any whoo i recently had a baby, and so i have all the creams and lotions and everything of the likes to take care of her beautiful baby skin, and sooo finally to the grain: i started to get a patch of psoriasis on my chin and i tried to put on normalface cream at every hour of the day and nothing helped, when finally...this might sound odd...but i put some diaper rash cream on it during the night, and i woke up and it was gone. So tonight i'm going to try and use the diaper rash cream on more of my skin to see if it can help because i've been living for years with this psoriasis that nothing else can help.
Try it! Baby diaper rash ointment.

I have never been told that I have psoriatic arthritis, but lately I have some swelling around my thumb joint (top of thumb). It doesn't hurt really, but is hot. Is this one of the symptoms to psoriatic arthritis?

Has anyone here had any odd internal problems? I have had chronic Pancreatitus. I just seems odd to me that I have P and PA and also another rare condition the Pancreatitus. My Gastro Dr. claims that there is no connection but I am sceptic. Right now I sit here with my gut jutting out swelled up and half luppy from Oxycotten.